Mammoth Biosciences IPO

Mammoth Biosciences, based in Brisbane, Calif., was founded in 2017 by Trevor Martin, the company’s CEO, and Janice Chen, Lucas Harrington, and Jennifer Doudna. The company, which was last valued at $1.08 billion in September 2021, is developing novel CRISPR systems to cure and detect diseases. CRISPR is a tool that can allow researchers to alter DNA sequences and modify gene function.

In November, the company was named to Fast Company’s 2022 list of the “Next Big Things in Tech.” In September 2021, the company raised $150 million in Series D financing from a group of investors including Redmile Group, Foresite Capital, Greenspring Associates and Senator Investment Group.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Mammoth Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Mammoth Biosciences

Forge green plus iconForge green minus icon

What is Mammoth Biosciences's IPO price?

The IPO price for Mammoth Biosciences will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Mammoth Biosciences?

Mammoth Biosciences is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Mammoth Biosciences shares pre-IPO?

If you own Mammoth Biosciences pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Mammoth Biosciences a publicly traded company?

Mammoth Biosciences is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is Mammoth Biosciences's funding to date?

Mammoth Biosciences has raised $365.12MM to date.
Forge green plus iconForge green minus icon

When was Mammoth Biosciences founded?

Mammoth Biosciences was founded in 2017.

Who are Mammoth Biosciences's major investors?

Mayfield Fund
Foresite Capital
Decheng Capital
Redmile Group

Mammoth Biosciences funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation

Series D-2

$107.74MM raised $XXX.XX $XXX.XX

Series D and D-1

$150MM raised $XXX.XX $XXX.XX

Series C and C-1

$45.11MM raised $XXX.XX $XXX.XX

Series B and B-1

$44.18MM raised $XXX.XX $XXX.XX

Series A

$18.1MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jun 16, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.